PAA

0.00%

19.5¢ pharmaust limited

Ann: First Patient Dosed in MND Phase 1/2 Trial, page-172

First 172 Last

Share
Profile

Follow
Jockthegreat

2,601 Posts.

1423

01/07/23

10:25

Post #: 68566117
Share

Originally posted by Densy: ↑

I'm pretty sure I've posted this before, but here's a reminder of why MPL vs MND looks so promising:

https://www.nature.com/articles/s41598-021-97405-1

For those who want to skip to the punchline...

In plain English, at doses greater than 0.4 micromoles, rapamycin seems to be working to down-regulate the mTOR C1 pathway and induce autophagy in motor neurones, clearing out the build-up of misformed proteins that are a hallmark of MND and 'rescuing' these cells.
But wait!
Once the dose of rapamycin exceeds 1 micromole, it becomes toxic. Toxicity also seems to increase over time, even at lower doses. So, while higher doses and extended treatment times may be better for inducing autophagy (which is what we're chasing) you also poison the patient. This is known as dose limiting toxicity.

This is why MPL look so promising!

As an mTOR inhibitor, preclinical research shows that MPL induces autophagy and clears misfolded proteins in a similar fashion to rapamycin but without with same dose-limiting toxicity. MPL is known to be a pretty benign drug.

As those who've seen the MND webinar will appreciate, a great deal of research and preparation has informed the trial and there are very good reasons to expect big things.

Now add in the apparent ability to more than double life expectancy in canine lymphoma (and how this is likely to translate to human cancer).

Plus the antiviral applications.

Of course I'd love it if PharmAust had an entire drug development department with hundreds of staff that could make it all happen at once - but we don't.

Which means everything takes longer, but it is most definitely happening people.

Cheers

Densy

Expand

An interesting post to revisit while we await the outcome on Tuesday...

PAA Price at posting: 7.5¢ Sentiment: Hold Disclosure: Held
7 Upvote

2 Great analysis

Reply

Top Stories

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

RCE

Recce's R327 found effective against E.coli during clinical trial

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Microcap Wrap: 5 explorers with news out today

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

First 172 Last

Add PAA (ASX) to my watchlist

(20min delay)
Last 19.5¢		Change 0.000(0.00%)		Mkt cap ! $86.55M

Open	High	Low	Value	Volume
19.5¢	19.5¢	18.5¢	$330.4K	1.741M

Buyers (Bids)

No.	Vol.	Price($)
1	4071	19.0¢

Sellers (Offers)

Price($)	Vol.	No.
19.5¢	24580	3

View Market Depth

No.	Vol.	Price($)
1	4071	0.190
12	453603	0.185
14	471449	0.180
8	743200	0.175
4	115882	0.170

Price($)	Vol.	No.
0.200	346149	3
0.205	55141	4
0.210	300000	2
0.215	459058	6
0.220	239679	2

Last trade - 16.10pm 28/06/2024 (20 minute delay)

PAA (ASX) Chart

Ann: First Patient Dosed in MND Phase 1/2 Trial, page-172

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Ava Risk Group expands US presence with A$0.7M Substation Deal

Recce's R327 found effective against E.coli during clinical trial

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Microcap Wrap: 5 explorers with news out today

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: First Patient Dosed in MND Phase 1/2 Trial, page-172

Top Stories

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Ava Risk Group expands US presence with A$0.7M Substation Deal

Recce's R327 found effective against E.coli during clinical trial

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Microcap Wrap: 5 explorers with news out today

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News